Roche (OTCQX:RHHBY) will collaborate with privately held Alcyone Lifesciences in precision drug delivery aimed at optimizing intrathecal (injected into the spinal canal) therapies and developing antisense oligonucleotide treatments for patients with neurological disorders.
Alcyone has developed a micro fabricated catheter called the Alcyone MEMS Cannula that enables the precise delivery of therapies to the brain and spinal cord. Their financial terms are not disclosed.